表观遗传特征支持B细胞前淋巴细胞白血病的诊断并识别2个临床生物学亚型
研究分析20例依据国际共识分类/世界卫生组织分类第四修订版指南诊断的B-PLL病例DNA甲基化组,并与CLL、MCL、SMZL及正常B细胞亚群比较。无监督主成分分析提示B-PLL在表观遗传上区别于CLL、MCL和SMZL,B-PLL可分为2个表观亚型,表观亚型1总体生存劣于表观亚型2。
要点
- B-PLL在表观遗传上区别于CLL、MCL和SMZL,有稳健的差异甲基化特征。
- B-PLL可分为2个表观亚型,表观亚型1免疫球蛋白重链可变区体细胞超突变较低。
- 表观亚型1富集MYC和SF3B1突变,总体生存劣于表观亚型2。
核心结论
- 本研究为B-PLL的生物学和鉴别诊断提供相关见解,并可能识别出2个具有不同生物学和临床特征的亚组。
研究设计与样本
- 分析20例依据国际共识分类/世界卫生组织分类第四修订版指南诊断的B-PLL病例的DNA甲基化组,并与慢性淋巴细胞白血病、套细胞淋巴瘤、脾边缘区淋巴瘤及正常B细胞亚群比较。
主要发现
- 无监督主成分分析提示B-PLL在表观遗传上区别于慢性淋巴细胞白血病、套细胞淋巴瘤和脾边缘区淋巴瘤,B-PLL中稳健的差异甲基化特征进一步支持这一点。
- B-PLL可分为2个具有不同临床生物学特征的表观亚型。
- 表观亚型1携带较低的免疫球蛋白重链可变区体细胞超突变和较表观亚型2更浅的生发中心相关DNA甲基化印记。
- 表观亚型1显著富集影响MYC和SF3B1的突变,并显示富集于MYC靶点的DNA低甲基化和基因上调特征。
- 尽管样本量小,表观亚型1患者的总体生存劣于表观亚型2患者。
局限性
- 尽管样本量小,表观亚型1患者的总体生存劣于表观亚型2患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recognition of B-cell prolymphocytic leukemia (B-PLL) as a separate entity is controversial based on the current classification systems. Here, we analyzed the DNA methylome of a cohort of 20 B-PLL cases diagnosed according to the guidelines of the International Consensus Classification/Fourth revised edition of the World Health Organization Classification, and compared them with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), splenic marginal zone lymphoma (SMZL), and normal B-cell subpopulations. Unsupervised principal component analyses suggest that B-PLL is epigenetically distinct from CLL, MCL, and SMZL, which is further supported by robust differential methylation signatures in B-PLL. We also observe that B-PLL can be segregated into 2 epitypes with differential clinicobiological characteristics. B-PLL epitype 1 carries lower immunoglobulin heavy variable somatic hypermutation and a less profound germinal center-related DNA methylation imprint than epitype 2. Furthermore, epitype 1 is significantly enriched in mutations affecting MYC and SF3B1, and displays DNA hypomethylation and gene upregulation signatures enriched in MYC targets. Despite the low sample size, patients from epitype 1 have an inferior overall survival than those of epitype 2. This study provides relevant insights into the biology and differential diagnosis of B-PLL, and potentially identifies 2 subgroups with distinct biological and clinical features.
引用
- Charalampopoulou S, Chapiro E, Nadeu F, et al. Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes. Blood Adv. 2024. PMID: 39471431. doi:10.1182/bloodadvances.2024013327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。